-
New
-
Tirzepatide
- Manufacturer: Hilma Biocare
Tirzepatide
Manufacturer: Hilma Biocare
Package: 10 mg
Common Names: Tirzepatide, Mounjaro
Info: Tirzepatide is a dual agonist targeting both the GIP and GLP-1 receptors. It is a synthetic analogue of gastric inhibitory polypeptide (GIP), a naturally occurring hormone in the human body that plays a crucial role in stimulating insulin secretion from the pancreas. The compound is a linear polypeptide made up of 39 amino acids, modified by lipidation to enhance its metabolic stability and improve cellular uptake.
Effects
Tirzepatide binds more strongly to GIP receptors than to GLP-1 receptors, and its dual agonist activity leads to a more effective reduction in elevated blood glucose levels compared to drugs targeting only the GLP-1 receptors. By mimicking the action of natural GIP, it activates the GIP receptor to stimulate insulin production. At the GLP-1 receptor, tirzepatide favors the production of cAMP (cyclic adenosine monophosphate), which plays a key role in regulating the metabolism of sugar, fat, and glycogen, over recruiting beta-arrestin. This unique dual action results in enhanced insulin secretion. Additionally, tirzepatide boosts levels of adiponectin and adipokines—key regulators of glucose and fat metabolism—with a significant peak increase of up to 26% after 26 weeks at a 10 mg dose.
The drug reaches peak concentrations 24-48 hours after administration and establishes a steady state after 4-5 weeks of continuous use. Its volume of distribution is 5.27 L, and its clearance rate is 0.0288 L/h. Renal impairment does not affect the pharmacokinetics of tirzepatide, and no dosage adjustments are required. Currently, no significant drug interactions have been identified.
Side Effects
Dosage Range and Duration of Use
Tirzepatide is administered through subcutaneous injection, typically once a week. The injection site is flexible and can be changed with each dose. The usual starting dose for adults is 2.5 mg, with the possibility of increasing to 5 mg, 7.5 mg, 10 mg, or even 15 mg, depending on how well the body tolerates the medication and the individual’s response. Always follow your doctor’s instructions regarding dosage adjustments.
Combination with Other Drugs
Tirzepatide is contraindicated in individuals with a history of medullary thyroid cancer or multiple endocrine neoplasia type 2, whether personal or familial. The drug’s effects on pancreatitis have not been studied extensively. It is also not recommended for patients with type 1 diabetes. Tirzepatide may interact with other medications, including insulin and other antidiabetic drugs, which could increase the risk of hypoglycemia. It can also interact with medications that affect gastrointestinal motility and certain antihypertensive medications. Before starting tirzepatide, inform your doctor of all the medications and supplements you are taking to avoid potential adverse interactions.
Tags: Tirzepatide, Mounjaro
